213 related articles for article (PubMed ID: 34815361)
1. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
[TBL] [Abstract][Full Text] [Related]
2. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
3. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Chang W; Altman MD; Lesburg CA; Perera SA; Piesvaux JA; Schroeder GK; Wyss DF; Cemerski S; Chen Y; DiNunzio E; Haidle AM; Ho T; Kariv I; Knemeyer I; Kopinja JE; Lacey BM; Laskey J; Lim J; Long BJ; Ma Y; Maddess ML; Pan BS; Presland JP; Spooner E; Steinhuebel D; Truong Q; Zhang Z; Fu J; Addona GH; Northrup AB; Parmee E; Tata JR; Bennett DJ; Cumming JN; Siu T; Trotter BW
J Med Chem; 2022 Apr; 65(7):5675-5689. PubMed ID: 35332774
[TBL] [Abstract][Full Text] [Related]
4. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
5. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
6. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
8. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
[TBL] [Abstract][Full Text] [Related]
10. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
[TBL] [Abstract][Full Text] [Related]
11. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
12. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Non-Nucleotide Small-Molecule STING Agonists
Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
[TBL] [Abstract][Full Text] [Related]
14. STING activation in cancer immunotherapy.
Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
16. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
18. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
19. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
[TBL] [Abstract][Full Text] [Related]
20. M335, a novel small-molecule STING agonist activates the immune response and exerts antitumor effects.
Zhao M; Fan W; Wang Y; Qiang P; Zheng Z; Shan H; Zhang M; Liu P; Wang Y; Li G; Li M; Hong L
Eur J Med Chem; 2024 Jan; 264():116018. PubMed ID: 38091891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]